Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844485 | 0.82 | MAPT (0.58) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1844681 | 0.81 | MAPT (0.54) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28408689 | 0.76 | ALDH1A1 (0.54) | MAPTNPSR1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL12497081 | 0.74 | APP (0.58) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1843205 | 0.73 | MAPT (0.82) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12684711 | 0.73 | APP (0.57) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8596155 | 0.71 | PARP14 (0.62) | ALDH1A1L3MBTL1PARP14PARP10 | |
| SCHEMBL27943660 | 0.71 | HTR6 (0.57) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1844939 | 0.71 | MAPT (0.62) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12684805 | 0.70 | MAPT (0.74) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
| EP-2320897-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | Treventis Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | MAPT 10/4885NPSR1 717/4885CYP1A2 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.